A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients
Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaran...
Gespeichert in:
Veröffentlicht in: | Gynecologic and obstetric investigation 2019-01, Vol.84 (1), p.99-106 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 106 |
---|---|
container_issue | 1 |
container_start_page | 99 |
container_title | Gynecologic and obstetric investigation |
container_volume | 84 |
creator | Sfakianoudis, Konstantinos Simopoulou, Mara Nitsos, Nikolaos Rapani, Anna Pantou, Agni Vaxevanoglou, Terpsithea Kokkali, Georgia Koutsilieris, Michael Pantos, Konstantinos |
description | Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaranteed towards successful management. Platelet-Rich Plasma (PRP) is a novel, highly promising approach that has been successfully applied for an array of medical issues. In this case series, we present 3 poor responder patients with the common denominator of: failed IVF attempts, poor oocyte yield, and poor embryo quality. The option of oocyte donation was rejected. All patients were treated with autologous PRP ovarian infusion following written consent. Within a 3-month interval, follicle-stimulating hormone decreased by 67.33%, while Anti-Müllerian hormone increased by 75.18%. These impressive results on the biochemical infertility markers alone are classified as a complete biological paradox, coupled by improved embryo quality. Results report a natural conception at 24 weeks, an uncomplicated healthy pregnancy at 17 weeks and a successful live birth. To our knowledge, this is the first time such an approach and results are reported, where PRP treatment on poor responders lead to overcoming their challenging reproductive barrier. |
doi_str_mv | 10.1159/000491697 |
format | Article |
fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_491697</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2092536455</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-fd2db805271821e17bb795d20dcd57ecfd204cf658fd4d1ccdfbe0b5f251af653</originalsourceid><addsrcrecordid>eNpt0M1LwzAYBvAgipvTg3eRgBc9VPPRrO1xDJ2DycZU0FNJkzdabZuZtIL_vRmbO3kKyfPLC--D0Ckl15SK7IYQEmd0mCV7qE9jxiNC2Ms-6hOepFHC42EPHXn_QUjAaXyIepxQHlzWR68jPJYe8CO4Ejy2DV5UsoUK2mhZqvf1zdcSL-HbVl1b2ka6H_wgG_kGNTQttgYvrHUB-JVtNDi8kG0ZEn-MDoysPJxszwF6vrt9Gt9Hs_lkOh7NIsV53EZGM12kRLCEpowCTYoiyYRmRCstElAhJ7EyQ5EaHWuqlDYFkEIYJqgMz3yALjdzV85-deDbvC69gqqSDdjO54xkTPBhLNb0akOVs947MPnKlXXYKKckXzeZ75oM9nw7titq0Dv5V10AZxvwKd0buB3Y_b_4N57MpxuRr7ThvwKkg1E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2092536455</pqid></control><display><type>article</type><title>A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients</title><source>MEDLINE</source><source>Karger Journals Complete</source><creator>Sfakianoudis, Konstantinos ; Simopoulou, Mara ; Nitsos, Nikolaos ; Rapani, Anna ; Pantou, Agni ; Vaxevanoglou, Terpsithea ; Kokkali, Georgia ; Koutsilieris, Michael ; Pantos, Konstantinos</creator><creatorcontrib>Sfakianoudis, Konstantinos ; Simopoulou, Mara ; Nitsos, Nikolaos ; Rapani, Anna ; Pantou, Agni ; Vaxevanoglou, Terpsithea ; Kokkali, Georgia ; Koutsilieris, Michael ; Pantos, Konstantinos</creatorcontrib><description>Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaranteed towards successful management. Platelet-Rich Plasma (PRP) is a novel, highly promising approach that has been successfully applied for an array of medical issues. In this case series, we present 3 poor responder patients with the common denominator of: failed IVF attempts, poor oocyte yield, and poor embryo quality. The option of oocyte donation was rejected. All patients were treated with autologous PRP ovarian infusion following written consent. Within a 3-month interval, follicle-stimulating hormone decreased by 67.33%, while Anti-Müllerian hormone increased by 75.18%. These impressive results on the biochemical infertility markers alone are classified as a complete biological paradox, coupled by improved embryo quality. Results report a natural conception at 24 weeks, an uncomplicated healthy pregnancy at 17 weeks and a successful live birth. To our knowledge, this is the first time such an approach and results are reported, where PRP treatment on poor responders lead to overcoming their challenging reproductive barrier.</description><identifier>ISSN: 0378-7346</identifier><identifier>EISSN: 1423-002X</identifier><identifier>DOI: 10.1159/000491697</identifier><identifier>PMID: 30134239</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Adult ; Anti-Mullerian Hormone - blood ; Female ; Fertilization in Vitro ; Follicle Stimulating Hormone - blood ; Humans ; Infertility, Female - blood ; Infertility, Female - therapy ; Live Birth ; Novel Insights from Clinical Practice ; Oocytes ; Ovulation Induction - methods ; Platelet-Rich Plasma ; Pregnancy ; Pregnancy Rate</subject><ispartof>Gynecologic and obstetric investigation, 2019-01, Vol.84 (1), p.99-106</ispartof><rights>2018 S. Karger AG, Basel</rights><rights>2018 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-fd2db805271821e17bb795d20dcd57ecfd204cf658fd4d1ccdfbe0b5f251af653</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30134239$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sfakianoudis, Konstantinos</creatorcontrib><creatorcontrib>Simopoulou, Mara</creatorcontrib><creatorcontrib>Nitsos, Nikolaos</creatorcontrib><creatorcontrib>Rapani, Anna</creatorcontrib><creatorcontrib>Pantou, Agni</creatorcontrib><creatorcontrib>Vaxevanoglou, Terpsithea</creatorcontrib><creatorcontrib>Kokkali, Georgia</creatorcontrib><creatorcontrib>Koutsilieris, Michael</creatorcontrib><creatorcontrib>Pantos, Konstantinos</creatorcontrib><title>A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients</title><title>Gynecologic and obstetric investigation</title><addtitle>Gynecol Obstet Invest</addtitle><description>Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaranteed towards successful management. Platelet-Rich Plasma (PRP) is a novel, highly promising approach that has been successfully applied for an array of medical issues. In this case series, we present 3 poor responder patients with the common denominator of: failed IVF attempts, poor oocyte yield, and poor embryo quality. The option of oocyte donation was rejected. All patients were treated with autologous PRP ovarian infusion following written consent. Within a 3-month interval, follicle-stimulating hormone decreased by 67.33%, while Anti-Müllerian hormone increased by 75.18%. These impressive results on the biochemical infertility markers alone are classified as a complete biological paradox, coupled by improved embryo quality. Results report a natural conception at 24 weeks, an uncomplicated healthy pregnancy at 17 weeks and a successful live birth. To our knowledge, this is the first time such an approach and results are reported, where PRP treatment on poor responders lead to overcoming their challenging reproductive barrier.</description><subject>Adult</subject><subject>Anti-Mullerian Hormone - blood</subject><subject>Female</subject><subject>Fertilization in Vitro</subject><subject>Follicle Stimulating Hormone - blood</subject><subject>Humans</subject><subject>Infertility, Female - blood</subject><subject>Infertility, Female - therapy</subject><subject>Live Birth</subject><subject>Novel Insights from Clinical Practice</subject><subject>Oocytes</subject><subject>Ovulation Induction - methods</subject><subject>Platelet-Rich Plasma</subject><subject>Pregnancy</subject><subject>Pregnancy Rate</subject><issn>0378-7346</issn><issn>1423-002X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0M1LwzAYBvAgipvTg3eRgBc9VPPRrO1xDJ2DycZU0FNJkzdabZuZtIL_vRmbO3kKyfPLC--D0Ckl15SK7IYQEmd0mCV7qE9jxiNC2Ms-6hOepFHC42EPHXn_QUjAaXyIepxQHlzWR68jPJYe8CO4Ejy2DV5UsoUK2mhZqvf1zdcSL-HbVl1b2ka6H_wgG_kGNTQttgYvrHUB-JVtNDi8kG0ZEn-MDoysPJxszwF6vrt9Gt9Hs_lkOh7NIsV53EZGM12kRLCEpowCTYoiyYRmRCstElAhJ7EyQ5EaHWuqlDYFkEIYJqgMz3yALjdzV85-deDbvC69gqqSDdjO54xkTPBhLNb0akOVs947MPnKlXXYKKckXzeZ75oM9nw7titq0Dv5V10AZxvwKd0buB3Y_b_4N57MpxuRr7ThvwKkg1E</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Sfakianoudis, Konstantinos</creator><creator>Simopoulou, Mara</creator><creator>Nitsos, Nikolaos</creator><creator>Rapani, Anna</creator><creator>Pantou, Agni</creator><creator>Vaxevanoglou, Terpsithea</creator><creator>Kokkali, Georgia</creator><creator>Koutsilieris, Michael</creator><creator>Pantos, Konstantinos</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201901</creationdate><title>A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients</title><author>Sfakianoudis, Konstantinos ; Simopoulou, Mara ; Nitsos, Nikolaos ; Rapani, Anna ; Pantou, Agni ; Vaxevanoglou, Terpsithea ; Kokkali, Georgia ; Koutsilieris, Michael ; Pantos, Konstantinos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-fd2db805271821e17bb795d20dcd57ecfd204cf658fd4d1ccdfbe0b5f251af653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Anti-Mullerian Hormone - blood</topic><topic>Female</topic><topic>Fertilization in Vitro</topic><topic>Follicle Stimulating Hormone - blood</topic><topic>Humans</topic><topic>Infertility, Female - blood</topic><topic>Infertility, Female - therapy</topic><topic>Live Birth</topic><topic>Novel Insights from Clinical Practice</topic><topic>Oocytes</topic><topic>Ovulation Induction - methods</topic><topic>Platelet-Rich Plasma</topic><topic>Pregnancy</topic><topic>Pregnancy Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sfakianoudis, Konstantinos</creatorcontrib><creatorcontrib>Simopoulou, Mara</creatorcontrib><creatorcontrib>Nitsos, Nikolaos</creatorcontrib><creatorcontrib>Rapani, Anna</creatorcontrib><creatorcontrib>Pantou, Agni</creatorcontrib><creatorcontrib>Vaxevanoglou, Terpsithea</creatorcontrib><creatorcontrib>Kokkali, Georgia</creatorcontrib><creatorcontrib>Koutsilieris, Michael</creatorcontrib><creatorcontrib>Pantos, Konstantinos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic and obstetric investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sfakianoudis, Konstantinos</au><au>Simopoulou, Mara</au><au>Nitsos, Nikolaos</au><au>Rapani, Anna</au><au>Pantou, Agni</au><au>Vaxevanoglou, Terpsithea</au><au>Kokkali, Georgia</au><au>Koutsilieris, Michael</au><au>Pantos, Konstantinos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients</atitle><jtitle>Gynecologic and obstetric investigation</jtitle><addtitle>Gynecol Obstet Invest</addtitle><date>2019-01</date><risdate>2019</risdate><volume>84</volume><issue>1</issue><spage>99</spage><epage>106</epage><pages>99-106</pages><issn>0378-7346</issn><eissn>1423-002X</eissn><abstract>Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaranteed towards successful management. Platelet-Rich Plasma (PRP) is a novel, highly promising approach that has been successfully applied for an array of medical issues. In this case series, we present 3 poor responder patients with the common denominator of: failed IVF attempts, poor oocyte yield, and poor embryo quality. The option of oocyte donation was rejected. All patients were treated with autologous PRP ovarian infusion following written consent. Within a 3-month interval, follicle-stimulating hormone decreased by 67.33%, while Anti-Müllerian hormone increased by 75.18%. These impressive results on the biochemical infertility markers alone are classified as a complete biological paradox, coupled by improved embryo quality. Results report a natural conception at 24 weeks, an uncomplicated healthy pregnancy at 17 weeks and a successful live birth. To our knowledge, this is the first time such an approach and results are reported, where PRP treatment on poor responders lead to overcoming their challenging reproductive barrier.</abstract><cop>Basel, Switzerland</cop><pmid>30134239</pmid><doi>10.1159/000491697</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-7346 |
ispartof | Gynecologic and obstetric investigation, 2019-01, Vol.84 (1), p.99-106 |
issn | 0378-7346 1423-002X |
language | eng |
recordid | cdi_karger_primary_491697 |
source | MEDLINE; Karger Journals Complete |
subjects | Adult Anti-Mullerian Hormone - blood Female Fertilization in Vitro Follicle Stimulating Hormone - blood Humans Infertility, Female - blood Infertility, Female - therapy Live Birth Novel Insights from Clinical Practice Oocytes Ovulation Induction - methods Platelet-Rich Plasma Pregnancy Pregnancy Rate |
title | A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A07%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Case%20Series%20on%20Platelet-Rich%20Plasma%20Revolutionary%20Management%20of%20Poor%20Responder%20Patients&rft.jtitle=Gynecologic%20and%20obstetric%20investigation&rft.au=Sfakianoudis,%20Konstantinos&rft.date=2019-01&rft.volume=84&rft.issue=1&rft.spage=99&rft.epage=106&rft.pages=99-106&rft.issn=0378-7346&rft.eissn=1423-002X&rft_id=info:doi/10.1159/000491697&rft_dat=%3Cproquest_karge%3E2092536455%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2092536455&rft_id=info:pmid/30134239&rfr_iscdi=true |